Guest edited by Professor Ben Marais (University of Sydney, Australia), this series of articles provides an overview of the global child tuberculosis burden and examines issues such as diagnosis, advances in treatment, and novel vaccination approaches. The series aims to address the needs of researchers, clinicians and other individuals who require up-to-date information on this topic.
Pneumonia is pleased to be still accepting submissions for this thematic series.
Pneumonia is a serious health concern, but it does not attract the attention it warrants. Perhaps this is due to a lack of understanding of the real extent of this infectious disease in the general population. Social networks offer a valuable tool for disseminating scientific information about pneumonia, increasing its visibility, and in general raising awareness about this preventable disease.
As a result of the significant disruption that is being caused by the COVID-19 pandemic we are very aware that many researchers will have difficulty in meeting the timelines associated with our peer review process during normal times. Please do let us know if you need additional time. Our systems will continue to remind you of the original timelines but we intend to be highly flexible at this time.
Pneumonia is the only journal to focus exclusively on pneumonia. Publishing original research, case reports, reviews, commentaries and correspondence, Pneumonia provides an international forum for the exchange of knowledge by scientists and clinicians involved in studying the etiology and pathogenesis of pneumonia, as well as its diagnosis, epidemiology, treatment and prevention. The journal's scope extends to research on lung infections and diagnosis, inflammation and immunity, microbial pathogenesis and viral-bacterial interactions.
Cutting-edge research, insightful reviews and dedication to the community make Pneumonia an essential resource for clinicians, researchers, respirologists and allied professionals involved with infectious diseases.
Pneumonia transferred to BioMed Central from Griffith University ePress in January 2016.
The archive of the journal has been transferred to a new platform and all articles previously published in the journal can be accessed here.
Pneumonia is published continuously online-only. We encourage you to sign up to receive free email alerts to keep up to date with all of the latest articles by registering here.
Professor Stephen I. Pelton is Professor of Pediatrics and Epidemiology at Boston University Schools of Medicine and Public Health in Massachusetts. He is also former Director of Pediatric Infectious Diseases at Boston Medical Center (BMC) and current Coordinator of Pediatric AIDS Program. Professor Pelton is an active clinician, investigator, a member of the Boston Medical University Campus Institutional Review Board, and mentor for trainees in Pediatric Infectious Diseases. He is principal investigator for the International Maternal Pediatric Adolescent AIDS Clinical Trials program (IMPAACT) at BMC that seeks to evaluate new strategies for prevention and treatment of HIV in children and adolescents. His laboratory is focused on vaccine-preventable diseases, especially those due to Streptococcus pneumoniae and new vaccines for prevention of respiratory tract infection due to nontypeable Haemophilus influenzae. Professor Pelton’s work has led to his recognition as a leading clinical scientist in studies of the impact of pneumococcal conjugate vaccine on invasive and respiratory tract disease in children. He has been named as one of Boston’s top Pediatric Infectious Diseases physicians by Boston Magazine for the past 5 years (2012–2017).
Professor Ger Rijkers, co-Editor-in-Chief, has studied the interaction between Streptococcus pneumoniae and the human immune system for most of his professional career. Being a biologist and medical immunologist by training, and working in hospital laboratories, his focus of research has been the cellular and molecular mechanisms of the immune response during infection and following vaccination. Special attention is given to the major risk groups: the young, the old, and the immunocompromised. He has published widely in the peer-reviewed literature, has presented at a great number of international scientific and medical conferences and has supervised many PhD students in their research. Professor Rijkers joined the Laboratory of Medical Microbiology and Immunology of the St Antonius Hospital in Nieuwegein, The Netherlands in 2006. As of 2012 he has been head of the Science Department of University College Roosevelt, Middelburg, The Netherlands.
Speed
134 days to first decision for reviewed manuscripts only
104 days to first decision for all manuscripts
166 days from submission to acceptance
20 days from acceptance to publication
Usage
162,281 Downloads
13 Altmetric mentions
